Celyad OncologyCLYYF 28 EBITDA Margin % is 66,262.50% as of Dec. 2025. GuruFocus rates CLYYF with a GF Score™ of 28/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 944 Biotechnology companies, Celyad Oncology ranks better than 99.68% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Celyad Oncology's EBITDA for the
six
months ended in Dec. 2025 was $5.30 Mil. Celyad Oncology's Revenue for the
six
months ended in Dec. 2025 was $0.01 Mil. Therefore, Celyad Oncology's EBITDA margin for the quarter that ended in Dec. 2025 was 66,262.50%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Celyad Oncology EBITDA Margin % Related Terms
Celyad Oncology EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Celyad Oncology's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLYYF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Celyad Oncology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celyad Oncology (CLYYF) has a EBITDA Margin % of 66,262.50% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Celyad Oncology and its competitors. According to the industry distribution chart, Celyad Oncology ranks #3 out of 944 companies in the Biotechnology industry, placing it in the top 0.3%.
Is Celyad Oncology's EBITDA Margin % too high?
Celyad Oncology's current EBITDA Margin % is 66,262.50%. Based on the distribution chart, Celyad Oncology ranks #3 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Celyad Oncology has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #3 out of 944 companies for EBITDA Margin %. This places Celyad Oncology in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Celyad Oncology and its competitors. Celyad Oncology's current EBITDA Margin % is 66,262.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.25 — trading 66.7% above its estimated fair value. The current EBITDA Margin % is 66,262.50%. Celyad Oncology's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current EBITDA Margin % is 66,262.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celyad Oncology (CLYYF) Overvalued in 2026?
Based on GuruFocus' analysis, Celyad Oncology stock appears to be overvalued.
The current stock price of $0.25 is trading 66.7% above its estimated GF Value™ of $0.15.
GuruFocus considers Celyad Oncology to be Significantly Overvalued.
Key valuation signals for CLYYF:
EBITDA Margin %: 66,262.50%
GF Value™: $0.15 vs. price of $0.25 (66.7% above fair value)
No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score
Get the complete analysis for CLYYF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
